Chain Reaction: Conquering Labeling Challenges in the Chemical Industry

February 28, 2020

Reversing the complexity of global labeling management in the chemicals industry, so that intensifying regulatory demands don’t encroach on international market opportunity Trust, transparency and, above all, the safety of process/supply-chain intermediaries and consumers, is of paramount importance to the global chemicals industry. Yet, increasingly-stringent regulations about product/substance-based declarations, hazard warnings, and use of mandatory safety statements and symbols, is taking its toll on international brands.

Spotlight

POXEL

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes. We have successfully completed our Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S. and EU and Japan. Our second program, PXL770, a direct AMPK activator, is in Phase 1 development. We intend to generate further growth through strategic partnerships and pipeline development. Imeglimin is the first in a new chemical class of oral anti-diabetic agents, the Glimins. Imeglimin acts on three main target organs involved in glucose homeostasis: the liver, muscle, and the pancreas.

OTHER WHITEPAPERS
news image

Digital Lifecycle Excellence in Energy & Utilities Industry E-Book

whitePaper | August 2, 2021

Learn how to apply physical and digital assets to deliver top performance across all categories. Today, modern energy and utility companies are faced with the complex task of getting more value from their physical assets and supporting data to improve efficiency and reduce costs. Using a digital lifecycle excellence approach to organize and consolidate that data will provide opportunities to increase competitiveness across your organization.

Read More
news image

The Sprint to the Summit: Unlocking Lab Efficiencythrough Digital Transformation

whitePaper | March 2, 2023

At such an important juncture in the evolution of India’s pharmaceutical sector, this white paper addresses several key facts about how generic pharma companies can rise to succeed.

Read More
news image

Cyber Resilience in the Oil and Gas Industry: Playbook for Boards and Corporate Officers

whitePaper | May 17, 2021

To help the energy industry improve its resilience against cyber risk, the World Economic Forum has convened over 40 senior executives to establish a blueprint for evaluating cyber risk across the oil and gas industry. This White Paper is the result of their in-depth discussions to illuminate the industry’s best practices and create new solutions for corporate leaders to address cyber risk. It presents six principles to help boards at oil and gas companies govern this risk and strengthen their organization’s cyber resilience. Adopting them will support the industry in its efforts to continue delivering safe, affordable and low-carbon energy for decades to come.

Read More
news image

Decarbonization Investment: Opportunities and Implications for EPCs

whitePaper | November 3, 2022

As sustainability targets drive the energy industry towards a net zero future and energy security concerns intensify, companies are challenged to meet these competing demands within financial and workforce restraints.

Read More
news image

Halides Chemicals Pvt. Ltd. - Combining Quality And Reliability In Every Formula

whitePaper | December 22, 2022

Halides Chemicals Pvt. Ltd. was incorporated in the year 1995. The company was formed with a view in mind to provide quality Halo Succinimides for pharmaceutical as well as chemical industry.

Read More
news image

Energy transition and decarbonization Pathways for the chemical industry

whitePaper | August 16, 2022

Like all industries, the chemical sector is under pressure to bring its operations and value chain on track toward a more sustainable and resilient energy future. In the medium and long term.

Read More

Spotlight

POXEL

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes. We have successfully completed our Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S. and EU and Japan. Our second program, PXL770, a direct AMPK activator, is in Phase 1 development. We intend to generate further growth through strategic partnerships and pipeline development. Imeglimin is the first in a new chemical class of oral anti-diabetic agents, the Glimins. Imeglimin acts on three main target organs involved in glucose homeostasis: the liver, muscle, and the pancreas.

Events